Fate Therapeutics Inc (FATE)

$5.04

-0.23

(-4.36%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Fate Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.94M → 1.67M (in $), with an average decrease of 13.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -52.75M → -44.12M (in $), with an average increase of 9.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 62.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 338.6%

Performance

  • $4.98
    $5.35
    $5.04
    downward going graph

    1.19%

    Downside

    Day's Volatility :6.83%

    Upside

    5.71%

    downward going graph
  • $1.63
    $8.83
    $5.04
    downward going graph

    67.66%

    Downside

    52 Weeks Volatility :81.54%

    Upside

    42.92%

    downward going graph

Returns

PeriodFate Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
21.71%
-0.7%
0.0%
6 Months
162.19%
6.6%
0.0%
1 Year
-15.41%
3.7%
-1.5%
3 Years
-93.38%
14.0%
-21.8%

Highlights

Market Capitalization
642.9M
Book Value
$3.74
Earnings Per Share (EPS)
-1.64
PEG Ratio
0.0
Wall Street Target Price
7.8
Profit Margin
-253.3%
Operating Margin TTM
-2098.75%
Return On Assets TTM
-18.32%
Return On Equity TTM
-37.76%
Revenue TTM
63.5M
Revenue Per Share TTM
0.65
Quarterly Revenue Growth YOY
-96.2%
Gross Profit TTM
-224.2M
EBITDA
-159.3M
Diluted Eps TTM
-1.64
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.96
EPS Estimate Next Year
-1.81
EPS Estimate Current Quarter
-0.52
EPS Estimate Next Quarter
-0.52

Analyst Recommendation

Hold
    42%Buy
    53%Hold
    3%Sell
Based on 26 Wall street analysts offering stock ratings for Fate Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 26 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
12
Hold
14
14
15
Sell
1
1
2

Analyst Forecast

What analysts predicted

Upside of 54.76%

Current $5.04
Target $7.80

Company Financials

FY18Y/Y Change
Revenue
4.7M
↑ 15.44%
Net Income
-66.6M
↑ 55.05%
Net Profit Margin
-1.4K%
↓ 358.94%
FY19Y/Y Change
Revenue
10.7M
↑ 125.32%
Net Income
-97.7M
↑ 46.71%
Net Profit Margin
-914.87%
↑ 490.15%
FY20Y/Y Change
Revenue
31.4M
↑ 194.33%
Net Income
-170.3M
↑ 74.29%
Net Profit Margin
-541.77%
↑ 373.1%
FY21Y/Y Change
Revenue
55.8M
↑ 77.66%
Net Income
-206.3M
↑ 21.14%
Net Profit Margin
-369.41%
↑ 172.36%
FY22Y/Y Change
Revenue
96.3M
↑ 72.44%
Net Income
-255.1M
↑ 23.63%
Net Profit Margin
-264.86%
↑ 104.55%
FY23Y/Y Change
Revenue
63.5M
↓ 34.03%
Net Income
-160.9M
↓ 36.9%
Net Profit Margin
-253.3%
↑ 11.56%
Q3 FY22Q/Q Change
Revenue
15.0M
↓ 19.24%
Net Income
-80.7M
↑ 16.84%
Net Profit Margin
-538.92%
↓ 166.39%
Q4 FY22Q/Q Change
Revenue
44.4M
↑ 196.08%
Net Income
-48.3M
↓ 40.17%
Net Profit Margin
-108.91%
↑ 430.01%
Q1 FY23Q/Q Change
Revenue
59.0M
↑ 32.97%
Net Income
-9.2M
↓ 81.02%
Net Profit Margin
-15.55%
↑ 93.36%
Q2 FY23Q/Q Change
Revenue
933.0K
↓ 98.42%
Net Income
-52.8M
↑ 475.3%
Net Profit Margin
-5.7K%
↓ 5638.79%
Q3 FY23Q/Q Change
Revenue
1.9M
↑ 108.36%
Net Income
-45.2M
↓ 14.38%
Net Profit Margin
-2.3K%
↑ 3330.78%
Q4 FY23Q/Q Change
Revenue
1.7M
↓ 13.79%
Net Income
-44.1M
↓ 2.32%
Net Profit Margin
-2.6K%
↓ 309.02%
FY18Y/Y Change
Total Assets
213.0M
↑ 102.32%
Total Liabilities
52.6M
↑ 87.04%
FY19Y/Y Change
Total Assets
302.3M
↑ 41.89%
Total Liabilities
57.5M
↑ 9.43%
FY20Y/Y Change
Total Assets
622.5M
↑ 105.92%
Total Liabilities
238.0M
↑ 313.8%
FY21Y/Y Change
Total Assets
921.5M
↑ 48.04%
Total Liabilities
242.6M
↑ 1.93%
FY22Y/Y Change
Total Assets
705.6M
↓ 23.43%
Total Liabilities
221.6M
↓ 8.65%
FY23Y/Y Change
Total Assets
506.2M
↓ 28.25%
Total Liabilities
137.8M
↓ 37.82%
Q3 FY22Q/Q Change
Total Assets
749.3M
↓ 7.15%
Total Liabilities
231.3M
↑ 2.11%
Q4 FY22Q/Q Change
Total Assets
705.6M
↓ 5.84%
Total Liabilities
221.6M
↓ 4.2%
Q1 FY23Q/Q Change
Total Assets
630.3M
↓ 10.66%
Total Liabilities
152.9M
↓ 31.02%
Q2 FY23Q/Q Change
Total Assets
584.8M
↓ 7.23%
Total Liabilities
147.0M
↓ 3.83%
Q3 FY23Q/Q Change
Total Assets
543.8M
↓ 7.01%
Total Liabilities
141.0M
↓ 4.08%
Q4 FY23Q/Q Change
Total Assets
506.2M
↓ 6.91%
Total Liabilities
137.8M
↓ 2.28%
FY18Y/Y Change
Operating Cash Flow
-38.7M
↑ 4.73%
Investing Cash Flow
-463.0K
↓ 95.46%
Financing Cash Flow
140.8M
↑ 196.73%
FY19Y/Y Change
Operating Cash Flow
-83.2M
↑ 115.2%
Investing Cash Flow
-157.5M
↑ 33907.13%
Financing Cash Flow
149.9M
↑ 6.5%
FY20Y/Y Change
Operating Cash Flow
-39.2M
↓ 52.84%
Investing Cash Flow
-161.1M
↑ 2.3%
Financing Cash Flow
282.8M
↑ 88.65%
FY21Y/Y Change
Operating Cash Flow
-162.9M
↑ 315.18%
Investing Cash Flow
-324.0M
↑ 101.16%
Financing Cash Flow
453.1M
↑ 60.21%
FY22Y/Y Change
Operating Cash Flow
-248.2M
↑ 52.4%
Investing Cash Flow
166.8M
↓ 151.46%
Financing Cash Flow
9.2M
↓ 97.97%
Q3 FY22Q/Q Change
Operating Cash Flow
-55.0M
↑ 3.55%
Investing Cash Flow
80.4M
↑ 99.51%
Financing Cash Flow
1.5M
↓ 56.34%
Q4 FY22Q/Q Change
Operating Cash Flow
-75.4M
↑ 36.95%
Investing Cash Flow
53.1M
↓ 33.92%
Financing Cash Flow
1.5M
↑ 2.02%
Q1 FY23Q/Q Change
Operating Cash Flow
-28.9M
↓ 61.72%
Investing Cash Flow
9.3M
↓ 82.41%
Financing Cash Flow
207.0K
↓ 86.35%
Q2 FY23Q/Q Change
Operating Cash Flow
-28.5M
↓ 1.27%
Investing Cash Flow
33.2M
↑ 255.11%
Financing Cash Flow
58.0K
↓ 71.98%

Technicals Summary

Sell

Neutral

Buy

Fate Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Fate Therapeutics Inc
Fate Therapeutics Inc
-25.14%
162.19%
-15.41%
-93.38%
-67.1%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Fate Therapeutics Inc
Fate Therapeutics Inc
NA
NA
0.0
-1.96
-0.38
-0.18
NA
3.74
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Fate Therapeutics Inc
Fate Therapeutics Inc
Hold
$642.9M
-67.1%
NA
-253.3%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Redmile Group, LLC

    13.23%

  • BlackRock Inc

    11.30%

  • Vanguard Group Inc

    9.36%

  • Bellevue Group AG

    4.89%

  • D. E. Shaw & Co LP

    4.75%

  • Johnson & Johnson

    3.41%

Corporate Announcements

  • Fate Therapeutics Inc Earnings

    Fate Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.

Organization
Fate Therapeutics Inc
Employees
181
CEO
Mr. J. Scott Wolchko
Industry
Health Technology

Discover More

FAQs